Schrodinger Inc (SDGR)
Debt-to-assets ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Total assets | US$ in thousands | 802,955 | 794,148 | 841,566 | 838,773 | 688,587 | 661,985 | 687,880 | 719,537 | 756,487 | 762,617 | 717,334 | 744,189 | 746,263 | 680,116 | 349,551 | 349,872 |
Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $802,955K
= 0.00
The debt-to-assets ratio for Schrodinger Inc has consistently been reported as 0.00 across all quarters for the years 2022 and 2023. This indicates that the company has not utilized any debt to finance its assets during this period. A debt-to-assets ratio of 0.00 suggests that the company's assets are entirely funded by equity, which may imply a low financial risk and high financial stability. However, it is essential to consider other financial metrics and qualitative factors to assess the company's overall financial health and performance.
Peer comparison
Dec 31, 2023
Company name
Symbol
Debt-to-assets ratio
Schrodinger Inc
SDGR
0.00
Abbott Laboratories
ABT
0.19
AbbVie Inc
ABBV
0.00
Alkermes Plc
ALKS
0.13
Amphastar P
AMPH
0.40
ANI Pharmaceuticals Inc
ANIP
0.31
Arcus Biosciences Inc
RCUS
0.00
Biomarin Pharmaceutical Inc
BMRN
0.09
Bristol-Myers Squibb Company
BMY
0.39
Catalent Inc
CTLT
0.00
Catalyst Pharmaceuticals Inc
CPRX
0.00